Sopping up SAP
by Tim Fulmer, Senior Writer
A team of European researchers has developed an antibody–small molecule combination that treats amyloidosis by lowering levels of a protein called serum amyloid P component in both circulation and solid organs. The therapy has shown efficacy in mouse models of the disease, and GlaxoSmithKline plc has exclusively in-licensed the IP. The pharma is preparing a humanized antibody against the protein for clinical studies.
A materia na integra está em:
http://www.nature.com/scibx/journal/v3/n45/full/scibx.2010.1341.html
Outra divulgação com o médico chefe desta pesquisa
Treatment for amyloidosis a step closer
http://www.ucl.ac.uk/news/news-articles/1010/10102002
Nenhum comentário:
Postar um comentário